Agenus | AGEN - Pre Tax Profit


Agenus reported $-10.61M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
J&J USD 4.97B 2.53B Dec/2025
Jiangsu Hengrui CNY 2.3B 934.54M Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
MacroGenics USD -14.93M 31.75M Dec/2025
Merck EUR 1.29B 458.1M Sep/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.64B 445M Dec/2025
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 40.63M 21.74M Dec/2025